20 December 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company developing the first safe, convenient, and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has commenced its series B funding round with an investment of US$20m from leading Australian life science investors, Brandon Capital and Tenmile. The funding will enable Aravax to […]
06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors. Dr Haumann is a pharma […]
Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board 4 March 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to […]
27 August 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, has appointed Principal Investigators for Phase 2 clinical trials of PVX108 in the United States and Australia. Aravax plans to submit its Investigational New Drug (IND) […]
13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, shared further data from a follow up study of PVX108 Phase 1 trial subjects at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2021 […]
01 November, 2020, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, announced today the appointment of Thomas Ulmer to the Board of Directors. Mr. Ulmer was previously the Chief Financial Officer of Immatics N.V., a NASDAQ-listed biopharmaceutical company and brings nearly […]
30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, has received positive feedback from the U.S Food and Drug Administration (FDA) in regard to its development plans for PVX108, a next generation, specific immunotherapy for […]
June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, today reported additional data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at […]
May 28, 2019, Melbourne, Victoria – Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present additional data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at the 2019 […]
February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advantages in safety and practicality, has presented its clinical trial results at one of the world’s most prominent […]
